vintafolide + carboplatin + paclitaxel

The combination of **vintafolide**, **carboplatin**, and **paclitaxel** is an experimental multi-agent chemotherapy regimen investigated primarily for the treatment of advanced ovarian cancer and other folate receptor-positive cancers. - **Vintafolide** is a folate-targeted vinca alkaloid conjugate (EC145) that selectively binds to folate receptors, which are frequently overexpressed in certain cancers, delivering the cytotoxic vinca alkaloid directly to tumor cells[3][9]. - **Carboplatin** is a platinum-containing compound that induces DNA cross-linking and apoptosis[5]. - **Paclitaxel** is a microtubule stabilizer that inhibits cell division, promoting apoptosis[5]. The rationale for combining these agents is their non-overlapping toxicity profiles and their synergistic or additive antitumor efficacy in preclinical and early clinical studies[3][1]. The combination has been studied in phase I clinical trials to assess tolerability and safety[1], and preclinical models have demonstrated significantly improved antitumor effects compared to single agents[3]. Vintafolide itself was initially developed by Endocyte and is most often paired with standard agents like platinum compounds (carboplatin) and taxanes (paclitaxel) to maximize cytotoxicity while targeting folate-receptor positive cells.

Other names

vintafolide + carboplatin + paclitaxel